Nivolumab+Sitravati...
 
Notifications
Clear all

Nivolumab+Sitravatinib Combo in clear cell renal cell carcinoma


NA
 NA
(@j)
Joined: 3 years ago
Posts: 531
Topic starter  

Combining a broad-spectrum tyrosine kinase inhibitor (TKI) with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary dose-finding trial involving patients with advanced clear cell renal cell carcinoma:

https://www.kcuk.org.uk/nivolumabsitravatinib-combo-impresses-in-rcc/


Quote
Share: